恆大健康(00708):恆馳電動車料明年下半年量產
恆大健康(00708)副主席劉永灼透露,上海及廣州生產基地首期規劃產能共40萬輛,下月起可試產,料明年下半年實現量產,期望正式銷售後很快可實現盈利及收支平衡。
公司於2018年底入股汽車銷售商廣匯汽車,他指出,廣匯擁有逾800個銷售網點,公司亦正計劃開設36個恆馳展示體驗中心、1,600家營銷中心及3,000個維修售後服務網點,相信在未來3至5年內年產銷可達100萬輛。
首席財務官潘大榮指,針對電動車業務2019年投資約147億元人民幣(下同),主要用於股權收購、基地建設、研發支出,今年上半年已投入30億元,下半年料再投入27億元以收購股權,明年計劃投資90億元,即總投資達到294億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.